Multiple sclerosis is a chronic immune-mediated disease of the central nervous system in which inflammatory demyelination and neurodegeneration disrupt neural transmission and cause variable neurological disability.
The global CNS biomarkers market is projected to reach USD 26.13 billion by 2035, amyloid beta therapeutics USD 26.50 billion, and calcineurin inhibitors USD 20.88 billion. AI integration is driving innovation across all three markets.
The EMA’s CHMP recommended approval of Sanofi’s Cenrifki (tolebrutinib) for non-relapsing secondary progressive multiple sclerosis. The phase 3 HERCULES study showed reduced disability progression, while liver injury remains an identified safety risk.
Merck is expanding its AI efforts through partnerships with Google Cloud and Mayo Clinic. The company said it will deploy AI across R&D and use multimodal clinical datasets to support drug discovery and precision medicine.
MSD signed a Google Cloud agreement worth up to $1 billion and entered an AI-focused R&D collaboration with Mayo Clinic. The deals expand AI use in drug discovery, development and broader operations.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
The FDA approved ScinoPharm Taiwan's glatiramer acetate as the first complex injectable generic for relapsing multiple sclerosis and Sentynl Therapeutics' copper histidinate as the first treatment for pediatric Menkes disease in January 2026. These approvals represent significant advancements in neurological care, with the glatiramer acetate approval following a novel regulatory pathway and the Menkes treatment showing improved survival in early-treated patients.
NeuroTherapia has completed a Phase 2a trial of NTRX-07 in Alzheimer's patients, meeting safety objectives with no treatment-related serious adverse events. Preliminary biomarker analysis shows encouraging results, including MRI findings trending toward stabilization. The oral small molecule targets neuroinflammation and showed positive effects in animal models.
Roche Holding AG shares show potential undervaluation despite strong returns, with DCF models suggesting 59% upside. The pharmaceutical giant trades at P/E ratios below fair value estimates while maintaining solid financial performance and dividend growth. Recent pipeline developments and product innovations support long-term growth prospects.
AI-powered drugmaker Earendil Labs secured $787 million to advance biologics for autoimmune diseases and cancer, while Immunic locked in up to $400 million to fund Phase 3 trials of its multiple sclerosis therapy.
Three recent studies reveal connections between gut microbiome composition and health outcomes, identifying specific bacterial groups associated with recovery and disease, plus genetic variants that shape microbial communities.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07597668 |
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations |
ACTIVE_NOT_RECRUITING | PHASE1 |
| NCT07595081 |
Propionic Acid for Multiple Sclerosis: Safety and Benefits |
COMPLETED | PHASE2/PHASE3 |
| NCT07593911 |
A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune Diseases |
NOT_YET_RECRUITING | NA |
| NCT07593807 |
TMS Combined With Virtual Reality and Multidisciplinary Rehabilitation in Multiple Sclerosis |
ACTIVE_NOT_RECRUITING | NA |
| NCT07589062 |
Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People With Multiple Sclerosis |
NOT_YET_RECRUITING | NA |
| NCT07587125 |
Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07582653 |
OCTive: A New Horizon in MS Digital Solution |
ENROLLING_BY_INVITATION | |
| NCT07580820 |
Gait Adaptability in Persons With MS Having Mild Disability |
RECRUITING | |
| NCT07578740 |
The Effects of High-Intensity Interval Training on Gait, Balance, and Cognitive Functions in Individuals With Multiple Sclerosis |
NOT_YET_RECRUITING | NA |
| NCT07573241 |
Single Arm Trial Identifying Barriers and Facilitators to Mindfulness Practice |
NOT_YET_RECRUITING | NA |
